Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 16/20 | 0.45 |
| ▸ | PPARA | Q07869 | 14/20 | 0.45 |
| ▸ | PPARG | P37231 | 11/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491350 | 0.91 | MAPT (0.44) | PPARDPPARAPPARGMAPTALDH1A1 | |
| SCHEMBL6490170 | 0.78 | PPARD (0.55) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6488927 | 0.77 | MRGPRX4 (0.44) | MAPT | |
| SCHEMBL6489283 | 0.75 | PPARD (0.47) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6500025 | 0.73 | NR1H4 (0.51) | NR1H4PPARDPPARAPPARGMAPT | |
| SCHEMBL6496733 | 0.73 | ALOX5AP (0.47) | PPARGSMN1; SMN2 | |
| SCHEMBL6489563 | 0.72 | SMN1; SMN2 (0.52) | PPARGMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6487982 | 0.71 | DCTPP1 (0.41) | PPARGSMN1; SMN2 | |
| SCHEMBL6490645 | 0.71 | PTGDR (0.44) | PPARGSMN1; SMN2 | |
| SCHEMBL6492692 | 0.70 | USP2 (0.45) | NR1H4PPARDPPARAPPARGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | NR1H4 1441/4885PPARD 290/4885PPARA 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.